CLLS Cellectis SA ADRs

Cellectis SA is a gene-editing company, employing its core proprietary technologies to develop products in the emerging field of immuno-oncology. Its two segment includes Therapeutics and Plants. This is an ADR of a company whose stock trades outside of the U.S. as the symbol FP:ALCLS.

$2.25  +0.10 (4.42%)
As of 12/08/2022 15:55:51 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  France
Country of incorporation:  France
IPO date:  03/25/2015
Outstanding shares:  45,567,810
Average volume:  98,111
Market cap:   $100,704,860
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BWFKZT2
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy